214 related articles for article (PubMed ID: 36804485)
1. Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal.
Talbot T; Lu H; Aboagye EO
Cancer Gene Ther; 2023 Jul; 30(7):955-963. PubMed ID: 36804485
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
Davis SJ; Sheppard KE; Pearson RB; Campbell IG; Gorringe KL; Simpson KJ
Clin Cancer Res; 2013 Mar; 19(6):1411-21. PubMed ID: 23362323
[TBL] [Abstract][Full Text] [Related]
3. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer.
Wrzeszczynski KO; Varadan V; Byrnes J; Lum E; Kamalakaran S; Levine DA; Dimitrova N; Zhang MQ; Lucito R
PLoS One; 2011; 6(12):e28503. PubMed ID: 22174824
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
[TBL] [Abstract][Full Text] [Related]
5. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
[TBL] [Abstract][Full Text] [Related]
6. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
Ahmed AA; Etemadmoghadam D; Temple J; Lynch AG; Riad M; Sharma R; Stewart C; Fereday S; Caldas C; Defazio A; Bowtell D; Brenton JD
J Pathol; 2010 May; 221(1):49-56. PubMed ID: 20229506
[TBL] [Abstract][Full Text] [Related]
7. Amplicon profiles in ovarian serous carcinomas.
Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
[TBL] [Abstract][Full Text] [Related]
8. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
Nakayama K; Nakayama N; Kurman RJ; Cope L; Pohl G; Samuels Y; Velculescu VE; Wang TL; Shih IeM
Cancer Biol Ther; 2006 Jul; 5(7):779-85. PubMed ID: 16721043
[TBL] [Abstract][Full Text] [Related]
9. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma.
Shih IeM; Nakayama K; Wu G; Nakayama N; Zhang J; Wang TL
Mod Pathol; 2011 May; 24(5):638-45. PubMed ID: 21240255
[TBL] [Abstract][Full Text] [Related]
10. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
Etemadmoghadam D; deFazio A; Beroukhim R; Mermel C; George J; Getz G; Tothill R; Okamoto A; Raeder MB; Harnett P; Lade S; Akslen LA; Tinker AV; Locandro B; Alsop K; Chiew YE; Traficante N; Fereday S; Johnson D; Fox S; Sellers W; Urashima M; Salvesen HB; Meyerson M; Bowtell D;
Clin Cancer Res; 2009 Feb; 15(4):1417-27. PubMed ID: 19193619
[TBL] [Abstract][Full Text] [Related]
11. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
12. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.
Kuhn E; Wang TL; Doberstein K; Bahadirli-Talbott A; Ayhan A; Sehdev AS; Drapkin R; Kurman RJ; Shih IeM
Mod Pathol; 2016 Oct; 29(10):1254-61. PubMed ID: 27443516
[TBL] [Abstract][Full Text] [Related]
13. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.
Kuo KT; Guan B; Feng Y; Mao TL; Chen X; Jinawath N; Wang Y; Kurman RJ; Shih IeM; Wang TL
Cancer Res; 2009 May; 69(9):4036-42. PubMed ID: 19383911
[TBL] [Abstract][Full Text] [Related]
14. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
[TBL] [Abstract][Full Text] [Related]
15. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
[No Abstract] [Full Text] [Related]
16. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
17. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.
Birch AH; Arcand SL; Oros KK; Rahimi K; Watters AK; Provencher D; Greenwood CM; Mes-Masson AM; Tonin PN
PLoS One; 2011; 6(12):e28250. PubMed ID: 22163003
[TBL] [Abstract][Full Text] [Related]
18. Histotype-specific copy-number alterations in ovarian cancer.
Huang RY; Chen GB; Matsumura N; Lai HC; Mori S; Li J; Wong MK; Konishi I; Thiery JP; Goh L
BMC Med Genomics; 2012 Oct; 5():47. PubMed ID: 23078675
[TBL] [Abstract][Full Text] [Related]
19. Amplification of 11q13 in ovarian carcinoma.
Brown LA; Kalloger SE; Miller MA; Shih IeM; McKinney SE; Santos JL; Swenerton K; Spellman PT; Gray J; Gilks CB; Huntsman DG
Genes Chromosomes Cancer; 2008 Jun; 47(6):481-9. PubMed ID: 18314909
[TBL] [Abstract][Full Text] [Related]
20. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
